{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:40:18Z","timestamp":1759974018994,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.medmal.2010.04.004","type":"journal-article","created":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T04:50:44Z","timestamp":1275972644000},"page":"568-573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bilan de l\u2019utilisation de la moxifloxacine dans le traitement de la tuberculose dans un h\u00f4pital universitaire"],"prefix":"10.1016","volume":"40","author":[{"given":"S.","family":"Berdot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Papy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rioux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Diamantis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ruimy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-C.","family":"Dombret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bouvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2010.04.004_bib1","unstructured":"Les cas de tuberculose maladie d\u00e9clar\u00e9s en France en 2007. Bulletin \u00e9pid\u00e9miologique hebdomadaire, 2009. (consult\u00e9 le 15\u00a0septembre, 2009, sur http:\/\/www.invs.sante.fr\/beh\/2009\/12_13\/beh_12_13_2009.pdf)."},{"key":"10.1016\/j.medmal.2010.04.004_bib2","unstructured":"Surveillance de la r\u00e9sistance aux antituberculeux en France\u00a0: donn\u00e9es r\u00e9centes. Bulletin \u00e9pid\u00e9miologique hebdomadaire, 2007. (consult\u00e9 le 15\u00a0septembre, 2009, sur http:\/\/www.invs.sante.fr\/beh\/2007\/11\/beh_11_2007.pdf)."},{"key":"10.1016\/j.medmal.2010.04.004_bib3","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0761-8425(04)71390-X","article-title":"When should standard treatment not be applied for the tuberculosis patient?","volume":"21","author":"Dautzenberg","year":"2004","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.medmal.2010.04.004_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medmal.2010.04.004_bib5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM199302253280802","article-title":"Treatment of 171\u00a0patients with pulmonary tuberculosis resistant to isoniazid and rifampin","volume":"328","author":"Goble","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2010.04.004_bib6","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM199510053331404","article-title":"Multidrug-resistant tuberculosis in patients without HIV infection","volume":"333","author":"Telzak","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2010.04.004_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jac\/44.3.393","article-title":"Activity of moxifloxacin against mycobacteria","volume":"44","author":"Gillespie","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2010.04.004_bib8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0924-8579(02)00239-X","article-title":"In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis","volume":"20","author":"Rodriguez","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2010.04.004_bib9","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1179\/joc.2004.16.4.334","article-title":"Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains","volume":"16","author":"Tortoli","year":"2004","journal-title":"J Chemother"},{"key":"10.1016\/j.medmal.2010.04.004_bib10","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.rmed.2006.01.002","article-title":"Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs","volume":"100","author":"Codecasa","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.medmal.2010.04.004_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","article-title":"Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis","volume":"169","author":"Nuermberger","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medmal.2010.04.004_bib12","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1128\/AAC.47.10.3117-3122.2003","article-title":"Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo","volume":"47","author":"Veziris","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2010.04.004_bib13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/AAC.48.3.780-782.2004","article-title":"Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study","volume":"48","author":"Pletz","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2010.04.004_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1164\/rccm.200603-360OC","article-title":"Moxifloxacin versus ethambutol in the first 2\u00a0months of treatment for pulmonary tuberculosis","volume":"174","author":"Burman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medmal.2010.04.004_bib15","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","article-title":"Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase\u00a0II trial","volume":"373","author":"Conde","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2010.04.004_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/rccm.200901-0078OC","article-title":"Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis","volume":"180","author":"Dorman","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medmal.2010.04.004_bib17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jinf.2008.05.005","article-title":"Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contra-indications or intolerance to rifamycins","volume":"57","author":"Bonora","year":"2008","journal-title":"J Infect"},{"key":"10.1016\/j.medmal.2010.04.004_bib18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0149-2918(04)90170-1","article-title":"Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies","volume":"26","author":"Ball","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.medmal.2010.04.004_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1179\/joc.2003.15.1.66","article-title":"Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results","volume":"15","author":"Valerio","year":"2003","journal-title":"J Chemother"},{"key":"10.1016\/j.medmal.2010.04.004_bib20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.medmal.2006.09.001","article-title":"Cardiac tolerance of moxifloxacin: clinical experience from a large observational French study in usual medical practice (Immediat study)","volume":"36","author":"Veyssier","year":"2006","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.medmal.2010.04.004_bib21","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1086\/598929","article-title":"Safety of fluoroquinolone use in patients with hepatotoxicity induced by antituberculosis regimens","volume":"48","author":"Ho","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2010.04.004_bib22","unstructured":"European medicines agency recommends restricting the use of oral moxifloxacin-containing medicines. European Medicines Agency, 2008. (consult\u00e9 le 20\u00a0septembre, 2008, sur http:\/\/www.ema.europa.eu\/pdfs\/human\/press\/pr\/38292708en.pdf)."},{"key":"10.1016\/j.medmal.2010.04.004_bib23","unstructured":"Information importante de pharmacovigilance. Moxifloxacine. Afssaps, 2008. (consult\u00e9 le 20\u00a0octobre, 2008, sur http:\/\/www.afssaps.fr\/Infos-de-securite\/Lettres-aux-professionnels-de-sante\/Information-importante-de-pharmacovigilance-concernant-IZILOX-Bayer-Sante)."},{"key":"10.1016\/j.medmal.2010.04.004_bib24","unstructured":"Point d\u2019information sur Izilox\u00ae (moxifloxacine). Modification des conditions d\u2019utilisation. Afssaps, 2008. (consult\u00e9 le 20\u00a0octobre, 2008, sur http:\/\/www.afssaps.fr\/Infos-de-securite\/Communiques-de-presse\/Izilox-R-moxifloxacine-modification-des-conditions-d-utilisation)."},{"key":"10.1016\/j.medmal.2010.04.004_bib25","unstructured":"Drug safety update. Latest advice for all medicines users. Medicines and healthcare products regulatory agency and commission on human medicines, 2008. (consult\u00e9 le 20\u00a0octobre, 2008, sur http:\/\/www.mhra.gov.uk\/Publications\/Safetyguidance\/DrugSafetyUpdate\/CON023078)."},{"key":"10.1016\/j.medmal.2010.04.004_bib26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","author":"Nijland","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2010.04.004_bib27","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1128\/AAC.01621-06","article-title":"Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin","volume":"51","author":"Weiner","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2010.04.004_bib28","unstructured":"Synth\u00e8se et recommandations du groupe de travail du Conseil Sup\u00e9rieur d\u2019Hygi\u00e8ne Publique de France (2002\u20132003). Traitement de la tuberculose-maladie. Rev Mal Respir 2003;20:S45\u201351."},{"key":"10.1016\/j.medmal.2010.04.004_bib29","unstructured":"Guide-Affection de longue dur\u00e9e. Tuberculose active. Haute Autorit\u00e9 de sant\u00e9, 2007. (consult\u00e9 le 20\u00a0octobre, 2008, sur http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/07-029_tuberculose-guide_edite_sans_lap.pdf)."},{"key":"10.1016\/j.medmal.2010.04.004_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1473-3099(08)70077-X","article-title":"Minimising moxifloxacin resistance with tuberculosis","volume":"8","author":"Drlica","year":"2008","journal-title":"Lancet Infect Dis"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X1000106X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X1000106X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:07:46Z","timestamp":1759972066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X1000106X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0399077X1000106X"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2010.04.004","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bilan de l\u2019utilisation de la moxifloxacine dans le traitement de la tuberculose dans un h\u00f4pital universitaire","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2010.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}